FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022984493> ?p ?o ?g. }

• W2022984493 endingPage "206" @default.
• W2022984493 startingPage "201" @default.
• W2022984493 abstract "BACKGROUND: Brain derived neurotrophic factor (BDNF) is a potent survival factor for motoneurons. This study investigated the safety and tolerability of recombinant methionyl ( r -metHuBDNF) infused intrathecally by means of an implanted pump in patients with ALS. METHODS: Twenty-five probable or definite ALS were treated with either r -metHuBDNF (25, 60, 150, 400 or 1000 mug/day) or placebo in a 12- week, randomized, double-blinded, sequential, dose-escalation study. Test treatment was interrupted by a washout period from days 11 to 25 to allow the evaluation of laboratory safety measures. In each dose cohort four patients received r -metHuBDNF and one received placebo. On completion of the double-blind period of the study all patients continued to receive r -metHuBDNF in an open-label extension for up to 60 weeks. Lumbar cerebrospinal fluid (CSF) samples were taken periodically from all patients for the measurement of r -metHuBDNF levels and in a minority of patients these were supplemented by cisternal samples. RESULTS: Within days after the initiation of infusion the majority of patients receiving r -metHuBDNF reported mild sensory symptoms, including paraesthesias or a human BDNF sense of warmth, which were usually confined to the lower limbs and were frequently exacerbated by neck flexion. In most instances these symptoms patients with decreased or even disappeared over several weeks. Sleep disturbance, dry mouth, agitation and other behavioural effects were encountered at higher doses (>150 mug/day) and necessitated dose reductions. The spinal CSF levels of r -metHuBDNF were directly related to dose, with a lumbar to cervical ratio of approximately 4:1. CONCLUSIONS: The intrathecal delivery of r -metHuBDNF in doses of up to 150 mug/day was well tolerated and appears feasible. The reversible CNS effects with higher dose indicate that BDNF can be delivered cranially against CSF flow. The small number of patients and the design of the study did not permit conclusions to be drawn about the efficacy of the treatment. (ALS 2000; 1:201-206)" @default.
• W2022984493 created "2016-06-24" @default.
• W2022984493 creator A5010420844 @default.
• W2022984493 creator A5014180821 @default.
• W2022984493 creator A5022587380 @default.
• W2022984493 creator A5025212570 @default.
• W2022984493 creator A5027837589 @default.
• W2022984493 creator A5027976216 @default.
• W2022984493 creator A5039862095 @default.
• W2022984493 creator A5042245285 @default.
• W2022984493 creator A5050184722 @default.
• W2022984493 creator A5070645055 @default.
• W2022984493 creator A5073709015 @default.
• W2022984493 date "2000-01-01" @default.
• W2022984493 modified "2023-10-05" @default.
• W2022984493 title "A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis" @default.
• W2022984493 cites W1571410849 @default.
• W2022984493 cites W1964177214 @default.
• W2022984493 cites W1996692121 @default.
• W2022984493 cites W2000079550 @default.
• W2022984493 cites W2018068734 @default.
• W2022984493 cites W2033818333 @default.
• W2022984493 cites W2037610799 @default.
• W2022984493 cites W2048710124 @default.
• W2022984493 cites W2076608010 @default.
• W2022984493 cites W2077770544 @default.
• W2022984493 cites W2083223959 @default.
• W2022984493 cites W2099690691 @default.
• W2022984493 doi "https://doi.org/10.1080/14660820050515197" @default.
• W2022984493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11464953" @default.
• W2022984493 hasPublicationYear "2000" @default.
• W2022984493 type Work @default.
• W2022984493 sameAs 2022984493 @default.
• W2022984493 citedByCount "254" @default.
• W2022984493 countsByYear W20229844932012 @default.
• W2022984493 countsByYear W20229844932013 @default.
• W2022984493 countsByYear W20229844932014 @default.
• W2022984493 countsByYear W20229844932015 @default.
• W2022984493 countsByYear W20229844932016 @default.
• W2022984493 countsByYear W20229844932017 @default.
• W2022984493 countsByYear W20229844932018 @default.
• W2022984493 countsByYear W20229844932019 @default.
• W2022984493 countsByYear W20229844932020 @default.
• W2022984493 countsByYear W20229844932021 @default.
• W2022984493 countsByYear W20229844932022 @default.
• W2022984493 countsByYear W20229844932023 @default.
• W2022984493 crossrefType "journal-article" @default.
• W2022984493 hasAuthorship W2022984493A5010420844 @default.
• W2022984493 hasAuthorship W2022984493A5014180821 @default.
• W2022984493 hasAuthorship W2022984493A5022587380 @default.
• W2022984493 hasAuthorship W2022984493A5025212570 @default.
• W2022984493 hasAuthorship W2022984493A5027837589 @default.
• W2022984493 hasAuthorship W2022984493A5027976216 @default.
• W2022984493 hasAuthorship W2022984493A5039862095 @default.
• W2022984493 hasAuthorship W2022984493A5042245285 @default.
• W2022984493 hasAuthorship W2022984493A5050184722 @default.
• W2022984493 hasAuthorship W2022984493A5070645055 @default.
• W2022984493 hasAuthorship W2022984493A5073709015 @default.
• W2022984493 hasConcept C126322002 @default.
• W2022984493 hasConcept C141071460 @default.
• W2022984493 hasConcept C142724271 @default.
• W2022984493 hasConcept C157820659 @default.
• W2022984493 hasConcept C197934379 @default.
• W2022984493 hasConcept C204787440 @default.
• W2022984493 hasConcept C27081682 @default.
• W2022984493 hasConcept C2778375690 @default.
• W2022984493 hasConcept C2779134260 @default.
• W2022984493 hasConcept C2779651940 @default.
• W2022984493 hasConcept C2780066322 @default.
• W2022984493 hasConcept C2780596555 @default.
• W2022984493 hasConcept C42219234 @default.
• W2022984493 hasConcept C44575665 @default.
• W2022984493 hasConcept C71924100 @default.
• W2022984493 hasConceptScore W2022984493C126322002 @default.
• W2022984493 hasConceptScore W2022984493C141071460 @default.
• W2022984493 hasConceptScore W2022984493C142724271 @default.
• W2022984493 hasConceptScore W2022984493C157820659 @default.
• W2022984493 hasConceptScore W2022984493C197934379 @default.
• W2022984493 hasConceptScore W2022984493C204787440 @default.
• W2022984493 hasConceptScore W2022984493C27081682 @default.
• W2022984493 hasConceptScore W2022984493C2778375690 @default.
• W2022984493 hasConceptScore W2022984493C2779134260 @default.
• W2022984493 hasConceptScore W2022984493C2779651940 @default.
• W2022984493 hasConceptScore W2022984493C2780066322 @default.
• W2022984493 hasConceptScore W2022984493C2780596555 @default.
• W2022984493 hasConceptScore W2022984493C42219234 @default.
• W2022984493 hasConceptScore W2022984493C44575665 @default.
• W2022984493 hasConceptScore W2022984493C71924100 @default.
• W2022984493 hasIssue "3" @default.
• W2022984493 hasLocation W20229844931 @default.
• W2022984493 hasLocation W20229844932 @default.
• W2022984493 hasOpenAccess W2022984493 @default.
• W2022984493 hasPrimaryLocation W20229844931 @default.
• W2022984493 hasRelatedWork W1966047811 @default.
• W2022984493 hasRelatedWork W2003042623 @default.
• W2022984493 hasRelatedWork W202460821 @default.
• W2022984493 hasRelatedWork W2068849886 @default.
• W2022984493 hasRelatedWork W2109235243 @default.

• next